TENAFLY, N.J.--(BUSINESS WIRE)--Every digital identity credential used to access and participate in the TransCelerate Shared Investigator Platform will comply with the global digital identity standard developed by SAFE-BioPharma Association. Widely used throughout the biopharmaceutical industry, the SAFE-BioPharma® standard ensures a high level of assurance that the individual using the credential is not somebody else.
The recently launched Shared Investigator Platform (SIP) provides a single point of access for interaction between investigator sites and multiple participating clinical trial sponsors. It offers central system access via one user account login and password and delivers harmonized processes, content and services. Participating TransCelerate member companies adopting the SIP can increase engagement with investigative sites and eliminate company-specific portal development and maintenance costs.
"Standardizing identity assurance is essential to being able to trust the identities of the investigators, researchers, executives and others with permission to enter individual portals for access to proprietary information and to exchange a wide variety of forms and confidential data," explains Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association. "It also allows investigators and their teams to use a single Internet identity to conduct sensitive business with their industry partners.
"This level of trust is necessary to comply with a broad array of laws and regulations protecting intellectual property, personal health data, and other confidential information. The SAFE-BioPharma standard provides the foundation – invisible in the background -- for the Shared Investigator Platform and all of its participants to collaborate efficiently and securely."
Because of the way each identity credential is bound to the individual's vetted identity, it provides a high level of assurance in the identity of the individual to whom it is issued. It also replaces the need for that individual to apply for and maintain multiple identity credentials. Additionally, the single credential can be used and trusted across multiple platforms, including all US government agencies.
The SAFE-BioPharma standard became operational in 2005. The association is a non-profit coalition of pharmaceutical companies concerned with standardizing identity trust.
TransCelerate Biopharma Inc. is a non-profit organization dedicated to simplifying and accelerating the research and development of innovative therapies. Its members include many of the world's largest biopharmaceutical companies. TransCelerate evolved from conversations at various forums for executive R&D leadership to discuss current issues facing the industry and to examine solutions for addressing common challenges.
For more information on the SAFE-BioPharma® standard for digital identity and digital signatures used in life science and healthcare settings, visit http://www.safe-biopharma.org.
SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Use of this trademark requires approval from SAFE-BioPharma Association.